The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | DLBCL updates at ASH 2021
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, provides key updates in the field of diffuse large B-cell lymphoma (DLBCL) that will be discussed at ASH 2021. He comments on the results from the Phase III ZUMA-7 trial (NCT03391466) which investigated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory (r/r) DLBCL. Dr Cheah additionally highlights potential data from the Phase III POLARIX trial (NCT03274492), which compared polatuzumab vedotin, an antibody-drug conjugate, with R-CHP against R-CHOP. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
